Class action lawsuits
MoonLake Immunotherapeutics Faces Securities Class Action Suit Over Phase 3 Trial Results
A securities class action lawsuit, Bridgewood v. MoonLake Immunotherapeutics, et al., has been filed against MoonLake (NASDAQ: MLTX) after the company announced disappointing Phase 3 trial results for its treatment candidate sonelokimab (SLK). Investors saw their shares plummet $55.75, or about 90%, on September 29, 2025. Hagens Berman, a